Abstract: The present invention provides a non-infectious immunotherapeutic containing retroviral particles devoid of outer envelope proteins or containing selected antigens isolated from a retrovirus. In one aspect, the immunogen is useful for immunizing an individual previously infected by a retrovirus including HIV, so as to induce factors against progression of the infection. In another aspect, there is provided a method of rendering a viral immunogen non-infectious. The immunogen may also be used to produce antibodies for passive immunotherapy, alone or in conjunction with active immunotherapy, in individuals infected with a retrovirus, including HIV, preferably those individuals exhibiting low levels of antibodies to retroviral gene products other than the outer envelope.

Abstract: The present invention provides vaccines and a means of vaccinating a mammal so as to prevent or control specific T cell mediated pathologies or to treat the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the mammal in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides a specific .beta.-chain variable region of the T cell receptor, designated V.beta.17, which is central to the pathogenesis of rheumatoid arthritis (RA).

Abstract: The present invention provides vaccines and a means of vaccinating a host so as to prevent or control specific T cell mediated pathologies. The vaccine is composed of a polypeptide whose amino acid sequence corresponds to a segment of the T cell receptor (TCR) present on the surface of the pathogenic T cells. The vaccine is administered to the host in a manner that induces an immune response directed against the TCR of pathologic T cells. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. Means of determining an appropriate amino acid sequence for such a vaccine are also provided.

Abstract: The present invention provides a non-infectious immunotherapeutic containing retroviral particles devoid of outer envelope proteins or containing selected antigens isolated from a retrovirus. There is also provided a vaccine effective against HIV. In one aspect, the immunogen is useful for immunizing an individual previously infected by a retrovirus including HIV, so as to induce immunoprotective factors protective against progression of the infection. In another aspect, the vaccine is useful for vaccinating an individual not previously infected with HIV in order to prevent subsequently acquired infection. In another aspect, there is provided a method of rendering a viral immunogen non-infectious. The immunogen may also be used to produce antibodies for passive immunotherapy, alone or in conjunction with active immunotherapy, in individuals infected with a retrovirus, including HIV, preferably those individuals exhibiting low levels of antibodies to retroviral gene products other than the outer envelope.

Abstract: Group B Streptococcus type-specific polysaccharides types I.sub.1, I.sub.b, II and III have been obtained from strains grown in a modified soy bean and yeast medium. These polysaccharides are useful as active or passive streptococcal vaccines.

Abstract: A high molecular weight capsular polysaccharide from H. influenza type b is an effective immunogenic agent against infection caused by the H. influenza type b bacterium.

Abstract: A high molecular weight capsular polysaccharide from H. influenza type b is an effective immunogenic agent against infection caused by the H. influenza type b bacterium.

Abstract: An antigenic, immunogenic, non-toxic complex is obtained from the cell surface of N. gonorrhoeae.

Abstract: A vaccine against dental caries is prepared from capsular polysaccharides (one or more strains), of Streptococcus pneumoniae.

Abstract: A vaccine against E. coli caused diarrhea is prepared from an isolate of the homogeneous heat-labile enterotoxin of human strain MB3353 of Escherichia coli, ATCC 31361, or of the porcine strain MB3708, ATCC 31362. The toxin, which is a protein, is a low molecular weight species of 10,000-13,000.

Abstract: A high molecular weight capsular polysaccharide from H. influenza type b is an effective immunogenic agent against infection caused by the H. influenza type b bacterium.

Abstract: A sub-cellular antigenic fraction of Bordetella bronchiseptica protects against the incidence and severity of swine atropic rhinitis.

Abstract: A vaccine against Group C meningococcal meningitis consisting of a polysaccharide of which at least 80% by weight has a molecular weight in excess of 1,000,000 daltons is prepared. The polysaccharide was isolated from Group C hexadecyl trimethylammonium bromide cell paste with 1.0M CaCl.sub.2 extraction and purified by phenol extraction, ultracentrifugation at 100,000 g. and ethanol fractionation (30%-45% v/v in ethanol).

Abstract: An antigenic, immunogenic, non-toxic complex is obtained from the cell surface of N. gonorrhoeae.

Abstract: A vaccine against E. coli caused diarrhea is prepared from an isolate of the homogeneous heat-labile enterotoxin of human strain MB3353 of Escherichia coli, ATCC 31361, or of the porcine strain MB3708, ATCC 31362. The toxin, which is a protein, is a low molecular weight species of 10,000-13,000.

Abstract: A sub-cellular antigenic fraction of Bordetella bronchiseptica protects against the incidence and severity of swine atropic rhinitis.

Abstract: A vaccine against Group C meningococcal meningitis consisting of a polysaccharide of which at least 80% by weight has a molecular weight in excess of 1,000,000 daltons is prepared. The polysaccharide was isolated from Group C hexadecyl trimethylammonium bromide cell paste with 1.0M CaCl.sub.2 extraction and purified by phenol extraction, ultracentrifugation at 100,000 g. and ethanol fractionation (30%-45% v/v in ethanol).

Abstract: Endotoxin contaminant in meningococcus group A and group C polysaccharide is removed by means of a phosphate containing adsorbent.